Triumvira Immunologics

About:

Triumvira Immunologics is an immunotherapy company that develops novel T cell therapies for cancer.

Website: https://triumvira.com

Top Investors: B Capital, Northpond Ventures, Viva Biotech, Leaps by Bayer, ATEM Capital Fund LP

Description:

Triumvira Immunologics, Inc. (“Triumvira”) is an immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co., with the vision of developing novel T cell therapies that are safer and more efficacious than current cancer treatments, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Their proprietary T cell Antigen Coupler (TAC) technology recruits the entire natural T cell receptor and is independent of the major histocompatibility complex (MHC), allowing for the development of better therapies for a broader range of patients with solid or liquid malignancies and also with diseases other than cancer.